ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's ...

6 September 2010, 12:28 am

LEUVEN, Belgium, September 6, 2010 /PRNewswire-FirstCall/ -- - Data Presented at EURETINA Highlight the Attractive Characteristics of this Novel Potential Treatment Option for Retinal Disorders ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that ...... Read More »

More Topics from "Articles"

• Blogs Last updated: September 7, 18:54
• Galapagos announces appointment of Howard Rowe to Board of Directors, increases share capital through warrant exercises
• BMO Jumps on Board Again as Sponsor of the 2010 BMO Nations' Cup at Spruce Meadows in Calgary
• Win tickets to Michelle Shocked, Whad'Ya Know, and more!
• The Ten Greatest England Goals of All-Time
• Madison eats agenda: Classes, watermelons, Chilimania, Thirsty Troll, Viva M'Atilde;'copy;xico
• Corneille, Artist of the Postwar Cobra Group, Dies at 88
• Jon Wertheim: Who replaces Patrick McEnroe as U.S. Davis Cup captain, best major, more mail
• 100+ Upcoming Social Media & Tech Events